- AIG Board OKs CEO Pay; Benmosche Agrees to Stay
- Mortgage Demand Slips as Rates Hold Near Lows
- Half of Banks' Losses May Still Be Hidden: IMF Head
- Deere Reports Quarterly Net Loss, Revenue Falls
- Tiffany Profit Higher Than Expected; Raises Outlook
- Americans Ditch Planes for Trains this Thanksgiving
- FDIC's Bair Cautions on Risks in Bank Break-Up Plan
- Call Me Crazy: Confessions of a Black Friday Shopper
- Turkey Day 101: How Well Do You Know Your Bird?
- Toyota Makes Recall Fix And So Long Saab
- Investors Bet on a New Year's Rally For eBay
- Why You Should Play the Reflation Trade: Stock Picker
- Citi Mortgage Reveals What Treasury Won't
- S&P to Hit 1,200 by Year-End: Chief Investor
- Amended Berkshire Hathaway Filing Indicates No Secret Stock Stakes at End of Q3
- Facebook's Biggest-Ever Holiday Shopping Season
- Facebook's New Dual Class Structure - Slow Steps to an IPO
- 5 Big Bank Stocks Investors Should Consider: Strategists
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Ritz-Carlton ?Struggling? in the US: President
- Obama Reiterates Commitment to Boost US-India Ties
- Americans Ditch Planes for Trains this Thanksgiving
- Australia Wheat Exporters Face Challenges: GrainCorp
- Starbucks Eyes China as Next Major Market
- The Social Media Gaming Threat
- Japan Export Rebound Eases Fear of New Recession
Text Size 
TOKYO, Nov 2 (Reuters) - Japan's Takeda Pharmaceutical and U.S. Amylin Pharmaceuticals said on Monday they will co-develop and commercialise drugs to treat obesity, including two Amylin drugs in mid-stage trials. Takeda, Japan's biggest drugmaker and best known for its diabetes drug Actos, will pay Amylin $75 million in a one-time up-front payment under the exclusive worldwide agreement. Amylin, maker of the diabetes drug Byetta, could also receive development and sales-based milestones worth more than $1 billion if the compounds in the agreement were successful, the companies said in a statement. The agreement includes Amylin's pramlintide/metreleptin and davalintide, which are in Phase II studies in the United States. Takeda will lead development activities beyond Phase II and all development activities outside the United States. It will shoulder 80 percent of U.S. development costs and 100 percent of costs for obtaining approval for products outside the United States. Takeda will lead product commercialisation and pay 100 percent of the costs for product commercialisation in and outside the United States, they said. (Reporting by Taiga Uranaka; Editing by Edwina Gibbs) ((taiga.uranaka@thomsonreuters.com; +81-3-6441-1813; Reuters Messaging: taiga.uranaka.reuters.com@reuters.net)) Keywords: TAKEDA AMYLIN/ (If you have a query or comment on this story, send an email to news.feedback.asia@thomsonreuters.com) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
Print
Email
- Remember when auto shows were major events where new models could generate buzz?
- CNBC’s Mike Huckman visits a cutting-edge plant to see how the flu vaccine of the future is being made.
- People who bottle up their anger at work are up to five times more likely to suffer a heart attack, a study found.
- Playboy will outsource its publishing operations in a bid to become profitable again.
- After nine years the NBA’s minor league equivalent is finally coming into its own.
- For nearly three decades, these on-call experts have been dishing advice on how to – and not to – cook turkey.
Data is a real-time snapshot *Data is delayed at least 15 minutes